Galapagos demonstrates commitment to immunology with new data in rheumatoid arthritis at EULAR 2023GlobeNewsWire • 05/22/23
Galapagos announces departure of Bart Filius, Chief Operating Officer and Chief Financial OfficerGlobeNewsWire • 05/02/23
Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritisGlobeNewsWire • 04/26/23
Galapagos' shareholders approve all resolutions proposed by the Board of Directors at the annual shareholders' meetingGlobeNewsWire • 04/25/23
Galapagos publishes 2022 annual report and announces Annual Shareholders' MeetingGlobeNewsWire • 03/23/23
Galapagos presented encouraging initial safety and efficacy data at 2023 EBMT-EHA for point-of-care manufactured CAR-T candidate, GLPG5201, in rrCLLGlobeNewsWire • 02/09/23
Galapagos shares down after announcing clinical-trial miss for Crohn's diseaseMarket Watch • 02/09/23
Galapagos announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohn's diseaseGlobeNewsWire • 02/08/23
Does Galapagos NV (GLPG) Have the Potential to Rally 34% as Wall Street Analysts Expect?Zacks Investment Research • 12/16/22
Galapagos and CellPoint presented encouraging initial data at ASH 2022 for GLPG5101, a CD19 CAR-T candidate manufactured at point-of-careGlobeNewsWire • 12/13/22
Down 5.9% in 4 Weeks, Here's Why Galapagos NV (GLPG) Looks Ripe for a TurnaroundZacks Investment Research • 12/08/22
Galapagos announces CHMP adoption of PRAC's recommendation for Jyseleca® following extensive safety review of all JAK inhibitorsGlobeNewsWire • 11/11/22
Galapagos to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022GlobeNewsWire • 11/08/22